PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March ...
PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose ...
PepGen Inc. PEPG shares are down during Tuesday’s premarket session following the announcement of topline results from the ...
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...
PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splici ...
Legal sleuths have discovered a new patent filed by Microsoft earlier this month that might hint at plans for its ...
PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 ...
PepGen Ltd (NASDAQ:PEPG) shares fell 44% in after-hours trading Monday following disappointing clinical trial results for its myotonic dystrophy type 1 treatment.
From smart printers to material innovations, stay ahead in 3D printing with these new gadgets that improve speed, quality, ...
Ranging from quantum mechanics to eating disorders to the nature of fiction, this is a breathtaking interrogation of family, connection and memory ...
Seeing Things, Marjorie Maddox’s most recent poetry collection, opens with a poem of ambivalent invocation: “darkness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results